| Literature DB >> 33133100 |
You Zhai1, Guanzhang Li1, Renpeng Li2, Yuanhao Chang1, Yuemei Feng1, Di Wang2, Fan Wu1, Wei Zhang2,3,4.
Abstract
Glioblastoma is one of the most common neoplasms in the central nervous system characterized by limited immune response and unlimited expansion capability. Cancer stem cells (GSCs), a small fraction of the tumor cells, possess a pivotal regulation capability in the tumor microenvironment with a superior proliferation ability. We aimed to reveal the interaction between glioma stem cells (GSCs) and immune cells during tumorigenesis. Single-cell sequencing data from seven surgical specimens of glioblastoma patients and patient-derived GSCs cocultured with peripheral leukocytes were used for the analysis. Cell grouping and trajectory analysis were performed using Seurat and Monocle 3 packages in R software. The gene set of Cancer Genome Anatomy Project was used to define different cell types. Cells with the ability of proliferation and differentiation in glioblastoma tissue were defined as GSCs, which had a similar expression pattern to that in the GSCs in vitro. Astrocytes in glioblastoma were mainly derived from differentiated GSCs, while oligodendrocytes were most likely to be derived from different precursor cells. No remarkable evolutionary trajectory was observed among the subgroups of T cells in glioblastoma. The immune checkpoint interaction between GSCs and immune cells was changed from stimulatory to inhibitory during tumorigenesis. The patient-derived GSCs system is an ideal model for GSC research. The above research revealed that the interaction pattern between GSC glioma stem cells and immune cells during tumorigenesis provides a theoretical basis for GSC glioma stem cell-targeted immunotherapy.Entities:
Keywords: T cell; glioma stem cell; immunosuppression; single cell sequence; tumorigenesis
Year: 2020 PMID: 33133100 PMCID: PMC7580180 DOI: 10.3389/fimmu.2020.581209
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 2Similarity of cell grouping in the coculture model and surgical specimens. (A) The GSCs and T cells were verified by immunofluorescence staining and flow cytometry. OSP: oligodendrocyte specific protein. (B) The subgroups of cells in the coculture model. (C) Markers of proliferation and immunology in different cell groups. (D) The similarity of glioma stem cells and lymphocytes in the coculture model and surgical specimens.
Figure 1Stratification and identification of cells from surgical specimens. (A) The subgroups of cells in surgical specimens. (B) The expression level of proliferation-associated biomarkers in different cell subgroups. (C) The PCA analysis of tumor cells in surgical samples. (D) Genes related to PC1 and PC2.
Figure 3Gene function analysis of glioma stem cells in the coculture model. (A) Gene numbers simultaneously expressed in glioma stem cells in both the coculture model and surgical specimens. (B) Enrichment analysis of biological functions for glioma stem cells in the coculture model. (C) Path enrichment analysis for glioma stem cells in the coculture model.
Figure 4Evolution routine of tumor cells in surgical specimens. (A) No significant batch difference in tumor cells from different surgical specimens. (B) Tumor cell subgrouping in surgical specimens. (C) The evolution direction of tumor cells in surgical specimens. (D) The pseudo-time sequence of evolution of tumor cells in surgical specimens.
Figure 5Evolution routine and function enrichment of lymphocytes in surgical specimens. (A) The evolution direction of lymphocytes in surgical specimens. (B) Enrichment analysis of biological functions for lymphocytes in the surgical specimens. (C) Pathway enrichment analysis for lymphocytes in the surgical specimens.
Figure 6Differences in the interaction pattern between tumor cells and immune cells in early and late stages of glioma. Changes in expression of immune checkpoints and the corresponding receptors in both immune cells (A) and glioma stem cells (B), in the early and late stages of glioma.